The Problem

  • Approximately, two in three Australians will be diagnosed with skin cancer by the time they are 70.
  • Melanoma is the most deadly form of skin cancer and is 3-4x more common in Australia compared to the US and UK.
  • Diagnosed early, treatment is simple, inexpensive and curative, despite this, it remains the leading cause of cancer death in young people (20-39yrs).
  • Screening guidelines are inconsistent and rely on subjective methods that have failed to reduce the mortality rate.
  • There are currently no specific blood tests available to diagnose or monitor melanoma progression and unlike most other cancer types, the mortality rate has INCREASED by 33% since the 1980s, and doubled since the ’60s.
  • Finally, over A$900 million is spent on skin cancer procedures and treatment every year, more than any other cancer type.


Diagnostic imprecision

A major challenge in addressing the melanoma mortality rate is the variability in diagnostic accuracy and precision. The conclusion from the largest ever study of melanoma diagnostic accuracy, performed by Dr. Joann Elmore at the University of Washington School of Medicine Seattle was:

Diagnoses spanning moderately dysplastic nevi to early stage invasive melanoma [are] neither reproducible nor accurateEfforts to improve clinical practice should include using a standardized classification system, acknowledging uncertainty in pathology reports, and developing tools such as molecular markers to support pathologists’ visual assessments. The British Medical Journal (BMJ) June  2017;

The Solution

Melaseq is a new internal approach to detecting melanoma. The test is being developed as a genomic blood-test which will assist doctors to diagnose and monitor melanoma more accurately and objectively. 

The test measures 38 circulating microRNAs, which are a recently-d

iscovered class of genes that exist outside of cells and can be used to differentiate between healthy and cancerous states.

Melanoma cells secrete microRNAs which circulate through the body and facilitate future metastatic events.

The Melaseq laboratory process is highly automated and based on a globally-available technology platform.

Combining an ‘internal’ assessment of disease state with existing imaging methods could reduce both over-diagnosis and mortality rates.

MelaSeq may also be useful for measuring response to surgery or immunotherapy, predicting prognosis/outcome and as an early sign of disease recurrence.